Company to Demonstrate Latest Advancements in Causal Machine Learning and AI for Trial Design and Predictive Analysis for Clinical Trial Success
PhaseV, a leader in AI/ML-driven clinical development, announced that it will demonstrate new capabilities of its platform for clinical trials at the upcoming Chief Medical Officer (CMO) Summit 360⁰ in Boston, MA.
Health Technology Insights:SE Healthcare’s AI Analytics Enhance Workforce Planning & Burnout
The new tools allow clinical development leaders such as CMOs, biostatisticians, and clinical operations professionals to seamlessly integrate learnings from previous clinical trials into trial design for future studies, bridging two processes that have traditionally been conducted separately.
“For the first time, clinical teams can leverage causal ML-driven insights from prior trials and real-world data to inform the design of future trials – all within a single, end-to-end multi-modal platform,” said Raviv Pryluk, PhD, CEO and Co-Founder of PhaseV. “This approach enables real-time evaluation of various parameters and their impact in order to increase the probability of success. By turning data analysis into actionable insights, we’re helping biotech and pharma companies reduce failure rates, optimize trial investments and improve patient outcomes.”
Health Technology Insights: Sparrow BioAcoustics Announces Limited Release of Stethophone PRO for Clinicians
PhaseV’s Causal to Adaptive capability integrates real-world and clinical trial data to improve planning, efficiency, and decision-making for future clinical trials. The Clinical Trial Success Prediction capability enables trial sponsors to quantify the probability of success by analyzing historical trial data, trial parameters and real-world evidence. By applying PhaseV’s proprietary statistical and AI methodologies to complex trial and patient datasets, this tool generates a probability score that supports more informed decision-making, reduces failure rates, and ultimately improves patient outcomes.
“Integrating causal ML and AI capabilities with Bayesian adaptive tools is unique and significantly more advanced than existing solutions currently available on the market,” said Brad Carlin, PhD, Senior Director of Data Science and Statistics at PhaseV. “Our platform is a true game-changer for the industry.”
Health Technology Insights: NovelVox Transforms Contact Centers with Zoom CX in Healthcare
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – PR Newswire
